Xenetic Biosciences is trading 5.95% down at $2.37, mainly amid broader risk-off trading, with no clear company-specific announcement identified on September 24, 2026. - XBI is down 2.04%, while major U.S. indexes are lower as Treasury yields and inflation concerns pressure growth stocks. - Its latest major development is the all-stock Santersus merger, announced September 16; existing shareholders would retain approximately 15% of the combined company. The merger may be a background volatility factor but is not a confirmed catalyst for this session.